Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine

Z Yang; K R Aubrey; I Alroy; Robert J Harvey; R J Vandenberg; J W Lynch

doi:10.1016/j.bcp.2008.07.037

Back

Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine

Journal article

Peer reviewed

Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine

Z Yang, K R Aubrey, I Alroy, Robert J Harvey, R J Vandenberg and J W Lynch

Biochemical Pharmacology, Vol.76(8), pp.1014-1023

2008

DOI: https://doi.org/10.1016/j.bcp.2008.07.037

Files and links (1)

url

https://doi.org/10.1016/j.bcp.2008.07.037View

Published Version

Abstract

cys-loop receptor

ligand-gated ion channel

nociception

analgesia

neurotransmission

endocannabinoid

HU-210

HU-308

WIN55,212-2

anandamide

N-arachidonyl-glycine

Glycine receptors (GlyRs) mediate inhibitory neurotransmission in spinal cord motor and pain sensory neurons. Recent studies demonstrated apparently contradictory (potentiating versus inhibitory) effects of the endocannabinoid anandamide on these receptors. The present study characterised the effects of cannabinoid agonists on α1, α1β, α2 and α3 GlyRs recombinantly expressed in HEK293 cells with the aims of reconciling effects of cannabinoids on these receptor subtypes and to establish the potential of different GlyR isoforms as novel physiological or analgesic targets for cannabinoids. The compounds investigated were anandamide, HU-210, HU-308, WIN55,212-2 and the endogenous non-cannabinoid, N-arachidonyl-glycine. The latter compound was chosen due to the structural similarity with anandamide and known analgesic actions in the spinal cord. Recombinant α1 and α1β GlyRs were potentiated by anandamide and HU-210 at submicromolar concentrations, whereas WIN55,212-2 had no effect and HU-308 produced only weak inhibition. By contrast, N-arachidonyl-glycine exerted complex effects including both potentiation and inhibition. Anandamide had no effect at α2 or α3 GlyRs although the other cannabinoids produced potent inhibition. On α2 GlyRs, the inhibitory potency sequence was HU-210 = WIN55,212-2 > HU-308 > N-arachidonyl-glycine but on α3 GlyRs it was HU-210 = WIN55212 = HU-308 > N-arachidonyl-glycine. These results suggest that α1, α2 and α3 containing GlyRs exhibit distinct pharmacological profiles for cannabinoids. We conclude that cannabinoid agonists may be useful as pharmacological tools for selectively inhibiting α2 and α3 GlyRs. Our results also establish GlyRs as potential novel targets for endogenous and exogenous cannabinoids. © 2008 Elsevier Inc. All rights reserved.

Details

Title: Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine
Authors: Z Yang (Author) - University of Queensland
K R Aubrey (Author) - University of Sydney
I Alroy (Author) - Pharmos Ltd., Israel
Robert J Harvey (Author) - School of Pharmacy, United Kingdom
R J Vandenberg (Author) - University of Sydney
J W Lynch (Author) - University of Queensland
Publication details: Biochemical Pharmacology, Vol.76(8), pp.1014-1023
Publisher: Elsevier Inc.
Date published: 2008
DOI: 10.1016/j.bcp.2008.07.037
ISSN: 0006-2952
Organisation Unit: School of Health; University of the Sunshine Coast, Queensland; School of Health and Sport Sciences - Legacy; Centre for Bioinnovation; School of Health and Behavioural Sciences - Legacy
Language: English
Record Identifier: 99450574102621
Output Type: Journal article

Metrics

1 File views/ downloads

286 Record Views

74 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Web Of Science research areas: Pharmacology & Pharmacy

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites